127 related articles for article (PubMed ID: 20514395)
21. High apoptotic index correlates to p21 and p27 expression indicating a favorable outcome of primary breast cancer patients, but lacking prognostic significance in multivariate analysis.
Schöndorf T; Göhring UJ; Becker M; Hoopmann M; Schmidt T; Rützel S; Rein DT; Ulrich U; Fechteler R; Bersch A; Mallmann P; Valter MM
Pathobiology; 2004; 71(4):217-22. PubMed ID: 15263811
[TBL] [Abstract][Full Text] [Related]
22. Insulin-like growth factor-1 and 17β-estradiol down-regulate prostate apoptosis response-4 expression in MCF-7 breast cancer cells.
Casolari DA; Pereira MC; de Bessa Garcia SA; Nagai MA
Int J Mol Med; 2011 Sep; 28(3):337-42. PubMed ID: 21567071
[TBL] [Abstract][Full Text] [Related]
23. p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2.
Vestey SB; Sen C; Calder CJ; Perks CM; Pignatelli M; Winters ZE
Breast Cancer Res; 2004; 6(5):R571-85. PubMed ID: 15318938
[TBL] [Abstract][Full Text] [Related]
24. Expression of prostate apoptosis response (Par-4) is associated with progesterone receptor in breast cancer.
Zapata-Benavides P; Méndez-Vázquez JL; González-Rocha TR; Zamora-Avila DE; Franco-Molina MA; Garza-Garza R; Rodriguez-Padilla C
Arch Med Res; 2009 Oct; 40(7):595-9. PubMed ID: 20082875
[TBL] [Abstract][Full Text] [Related]
25. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
26. CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.
Liu F; Lang R; Zhao J; Zhang X; Pringle GA; Fan Y; Yin D; Gu F; Yao Z; Fu L
Breast Cancer Res Treat; 2011 Nov; 130(2):645-55. PubMed ID: 21717105
[TBL] [Abstract][Full Text] [Related]
27. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
28. SPOCK1 Is a Novel Transforming Growth Factor-β-Induced Myoepithelial Marker That Enhances Invasion and Correlates with Poor Prognosis in Breast Cancer.
Fan LC; Jeng YM; Lu YT; Lien HC
PLoS One; 2016; 11(9):e0162933. PubMed ID: 27626636
[TBL] [Abstract][Full Text] [Related]
29. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
[TBL] [Abstract][Full Text] [Related]
31. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
32. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
[TBL] [Abstract][Full Text] [Related]
33. Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival.
Serra KP; Peres RM; Sarian LO; Vassallo J; Pinto GA; Silva GR; Soares FA; da Cunha IW; Espinola J; Bento AM; Del Corso LM; Derchain S
Acta Histochem; 2016 Mar; 118(2):176-82. PubMed ID: 26791786
[TBL] [Abstract][Full Text] [Related]
34. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic correlation of beclin-1 and bcl-2 expression in human breast cancer.
Won KY; Kim GY; Kim YW; Song JY; Lim SJ
Hum Pathol; 2010 Jan; 41(1):107-12. PubMed ID: 19762066
[TBL] [Abstract][Full Text] [Related]
36. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
37. Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence.
Okroj M; Holmquist E; Nilsson E; Anagnostaki L; Jirström K; Blom AM
Cancer Immunol Immunother; 2015 Apr; 64(4):467-78. PubMed ID: 25618258
[TBL] [Abstract][Full Text] [Related]
38. ESPL1 is a candidate oncogene of luminal B breast cancers.
Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
[TBL] [Abstract][Full Text] [Related]
39. High snail expression predicts a poor prognosis in breast invasive ductal carcinoma patients with HER2/EGFR-positive subtypes.
Chang HY; Tseng YK; Chen YC; Shu CW; Lin MI; Liou HH; Fu TY; Lin YC; Ger LP; Yeh MH; Liu PF
Surg Oncol; 2018 Jun; 27(2):314-320. PubMed ID: 29937187
[TBL] [Abstract][Full Text] [Related]
40. Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.
Karn T; Ruckhäberle E; Hanker L; Müller V; Schmidt M; Solbach C; Gätje R; Gehrmann M; Holtrich U; Kaufmann M; Rody A
Breast Cancer Res Treat; 2011 Nov; 130(2):409-20. PubMed ID: 21203899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]